“Alpha-9’s radiopharmaceuticals are designed to treat a range of solid and hematologic cancers such as prostate cancer, breast cancer, leukemia and lymphoma. According to Dr. David Hirsch, chief executive officer of Alpha-9, the $75 million in Series B financing will enable the company to bring its first five treatments into clinical trials with patients over the next two years.

‘Thanks to the cutting-edge research at UBC, these radiotherapies have tremendous potential to address a wide range of cancers,’ says Dr. Hirsch. ‘In the coming years, we plan to progress multiple treatments into first-in-human clinical trials, harnessing the potential of radiopharmaceuticals to realize more effective treatments for people living with cancer.’”

Learn more on UBC biotech spin-off raises $75M to bring cancer treatments to patients via UBC Faculty of Medicine

Published by UBC Abbotsford-Mission Family Practice Residency Program